How Boehringer Ingelheim Deepened Its Digital Transformation
While many pharma companies have integrated digital tools like cloud services into their operations, some are later adopters. Boehringer Ingelheim is one of the most recent companies to announce a move to a cloud-based R&D platform as part of the company’s commitment to digital transformation. For those still considering how to go about the shift to digital, rolling things out in the right order is one important factor, an EY expert tells In Vivo.
You may also be interested in...
Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.
Using machine learning, PhaseV, an Israeli startup is trying to make adaptive trial design more accessible. It is early days, but the company's approach is attracting investors and partners.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.